Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy

NCT07706088 · Not yet recruiting

Last updated 2026-07-28

This clinical trial is testing whether tirzepatide, a medication, can help people with diabetes-related nerve damage in their feet and legs.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-07 · est. completion 2028-07

What this study is testing ClinicalTrials.gov NCT07706088 ↗

Description as written by the study sponsor.

Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.

Treatments tested

Tirzepatide 2.5mg weekly Drug

tirzepatide will be initiated at 2.5 mg weekly and dose will be escalated to 7.5 mg weekly depending upon tolerance and changes in parameters from baseline as described as outcomes
all standard of care to diabetic patient besides tirzepatide Drug

diabetic patient will receive all standard of care beside tirzepatide

Main thing measured	To assess the percent change in CNFD compared to baseline
Sponsor	Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions studied	Neuropathy, Small Fiber, Diabete Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07706088 ↗